Is Moderna Inc (NASDAQ: MRNA) Stock Worth Investing In for High Returns?

In the last trading session, 3.54 million Moderna Inc (NASDAQ:MRNA) shares changed hands as the company’s beta touched 1.63. With the company’s per share price at $78.96 changed hands at $2.52 or 3.30% during last session, the market valuation stood at $30.11B. MRNA’s last price was a discount, traded about -175.14% off its 52-week high of $217.25. The share price had its 52-week low at $62.55, which suggests the last value was 20.78% up since then. When we look at Moderna Inc’s average trading volume, we note the 10-day average is 4.0 million shares, with the 3-month average coming to 4.22 million.

Analysts gave the Moderna Inc (MRNA) stock a consensus recommendation rating of an Overweight, calculated at a mean rating of 2.24. If we narrow down to specifics, the data shows that 2 out of 25 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 11 recommended MRNA as a Hold, 11 felt it is a Buy and 0 rated the stock as Underweight. Moderna Inc’s EPS for the current quarter is expected to be -$1.28.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Moderna Inc (NASDAQ:MRNA) trade information

Instantly MRNA was in green as seen at the end of in last trading. With action 12.46%, the performance over the past five days has been green. The jump to weekly highs of 79.80 on Monday, 11/20/23 added 3.30% to the stock’s daily price. The company’s shares are showing year-to-date downside of -56.04%, with the 5-day performance at 12.46% in the green. However, in the 30-day time frame, Moderna Inc (NASDAQ:MRNA) is -1.79% down. Looking at the short shares, we see there were 19.61 million shares sold at short interest cover period of 4.81 days.

The consensus price target for the stock as assigned by Wall Street analysts is $135.24, meaning bulls need an upside of 41.61% from its current market value. According to analyst projections, MRNA’s forecast low is $52.00 with $300.00 as the target high. To hit the forecast high, the stock’s price needs a -279.94% plunge from its current level, while the stock would need to tank 34.14% for it to hit the projected low.

Moderna Inc (MRNA) estimates and forecasts

Data shows that the Moderna Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -37.70% over the past 6 months, a -162.43% in annual growth rate that is considerably lower than the industry average of 14.90%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Moderna Inc will fall -135.50%, while the growth in revenue is estimated to hit -1,468.40% for the next quarter. Year-over-year growth is forecast to reach -69.90% down from the last financial year.

Consensus estimates given by 13 financial analysts project the company’s revenue in the current quarter to hit an average of $2.2 billion. 6 analysts are of the opinion that Moderna Inc’s revenue for the quarter ending Mar 2024 will be $634.78 million. The company’s revenue for the corresponding quarters a year ago was $5.08 billion and $1.86 billion respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -56.60%. The estimates for the next quarter sales put growth at -65.90%.

The 2023 estimates are for Moderna Inc earnings to decrease by -157.48%.

MRNA Dividends

Moderna Inc is expected to release its next quarterly earnings report on November 02.

Moderna Inc (NASDAQ:MRNA)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 9.69% of Moderna Inc shares while 69.48% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 76.93%. There are 69.48% institutions holding the Moderna Inc stock share, with Baillie Gifford and Company the top institutional holder. As of Jun 29, 2023, the company held 12.01% of the shares, roughly 45.71 million MRNA shares worth $5.55 billion.

Vanguard Group Inc holds the second largest percentage of outstanding shares, with 7.22% or 27.46 million shares worth $3.34 billion as of Jun 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Vanguard International Growth Fund. With 10.11 million shares estimated at $1.23 billion under it, the former controlled 2.66% of total outstanding shares. On the other hand, Vanguard International Growth Fund held about 2.47% of the shares, roughly 9.42 million shares worth around $1.2 billion.

On Key

Related Posts